Similar articles

• Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.

  Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S. Beresniak A, et al. Clin Exp Rheumatol. 2013 May-Jun;31(3):400-8. Epub 2013 Mar 4. Clin Exp Rheumatol. 2013. PMID: 23464803
• Trials reveal promising options for treating juvenile rheumatoid arthritis.

  Hampton T. Hampton T. JAMA. 2008 Jan 2;299(1):27-8. doi: 10.1001/jama.2007.36. JAMA. 2008. PMID: 18167400 No abstract available.
• Comparison between adalimumab, etanercept, and infliximab in rheumatoid arthritis: comment on the article by Hetland et al.

  Francis S, Block MJ. Francis S, et al. Arthritis Rheum. 2010 Sep;62(9):2826; author reply 2826-8. doi: 10.1002/art.27606. Arthritis Rheum. 2010. PMID: 20556822 No abstract available.
• [Effectiveness of TNF antagonists in routine clinical practice and costs].

  Prokes M. Prokes M. Vnitr Lek. 2009 Jan;55(1):45-53. Vnitr Lek. 2009. PMID: 19227955 Review. Czech.
• Anti-TNF agents for rheumatoid arthritis.

  Seymour HE, Worsley A, Smith JM, Thomas SH. Seymour HE, et al. Br J Clin Pharmacol. 2001 Mar;51(3):201-8. doi: 10.1046/j.1365-2125.2001.00321.x. Br J Clin Pharmacol. 2001. PMID: 11298065 Free PMC article. Review.